Next Article in Journal
Transcriptome and Gene Ontology (GO) Enrichment Analysis Reveals Genes Involved in Biotin Metabolism That Affect l-Lysine Production in Corynebacterium glutamicum
Previous Article in Journal
MicroRNAs in Osteoclastogenesis and Function: Potential Therapeutic Targets for Osteoporosis
Previous Article in Special Issue
Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation
Article

A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection

1
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Kaisei Hospital, Osaka City, Osaka 532-0003, Japan
2
Laboratory of Host Defenses Institute for Advanced Medical Science, Hyogo College of Medicine, Nishinomiya City, Hyogo 668-8501, Japan
3
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Hospital of Japan Community Healthcare Organization, Osaka city, Osaka 553-0003, Japan
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Tatsuo Kanda
Int. J. Mol. Sci. 2016, 17(3), 350; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17030350
Received: 23 December 2015 / Revised: 19 February 2016 / Accepted: 24 February 2016 / Published: 9 March 2016
(This article belongs to the Special Issue Viral Hepatitis Research)
The restoration of innate immune responses has potential as a novel therapeutic strategy for chronic hepatitis C (CHC). We compared the efficacy and safety of induction therapy (IT) with natural interferon-β (n-IFN-β) followed by pegylated-IFN-α/ribavirin (PR) alone (group A, n = 30) and IT with a protease inhibitor (PI) (simeprevir or vaniprevir)/PR (group B, n = 13) in CHC patients with genotype 1b and high viral loads. During IT with nIFN-β, virologic response rates in group A and group B were 10% and 8% (p = 0.6792) at week 4, 30% and 16% (p = 0.6989) at week 12 and 47% and 20% (p = 0.0887) at week 24 respectively. During and after the treatment with PR alone or PI/PR, virologic response rates in groups A and B were 50% and 82% (p = 0.01535) at week 4, 53% and 91% (p = 0.006745) at week 8, 57% and 91% (p = 0.001126) at week 12, 57% and 100% (p < 0.001845) at the end of the treatment and 57% and 80% (p < 0.005166) after treatment cessation. IT with PI/PR linked to the restoration of innate immune response was tolerated well, overcame virological breakthrough, enhanced early virologic responses, and resulted in a sustained virologic response in difficult-to-treat CHC patients. IT with PI/PR is beneficial for treating difficult-to-treat CHC patients. View Full-Text
Keywords: chronic hepatitis C; protease inhibitor; Peg-IFN-α; ribavirin; interferon-β; induction therapy chronic hepatitis C; protease inhibitor; Peg-IFN-α; ribavirin; interferon-β; induction therapy
Show Figures

Graphical abstract

MDPI and ACS Style

Kishida, Y.; Imaizumi, N.; Tanimura, H.; Kashiwamura, S.; Kashiwagi, T. A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection. Int. J. Mol. Sci. 2016, 17, 350. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17030350

AMA Style

Kishida Y, Imaizumi N, Tanimura H, Kashiwamura S, Kashiwagi T. A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection. International Journal of Molecular Sciences. 2016; 17(3):350. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17030350

Chicago/Turabian Style

Kishida, Yutaka, Naohiko Imaizumi, Hirohisa Tanimura, Shinichiro Kashiwamura, and Toru Kashiwagi. 2016. "A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection" International Journal of Molecular Sciences 17, no. 3: 350. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17030350

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop